Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

[pSer139]Histone H2AX polyclonal antibody

 
ADI-905-771-100 100 µg 319.00 USD
Do you need bulk/larger quantities?
 

Product Specification

Host:Rabbit
 
Immunogen:Synthetic peptide corresponding to human Histone H2AX phosphorylated at Ser139.
 
UniProt ID:P16104
 
Species reactivity:Human
 
Applications:WB
 
Purity Detail:Peptide affinity purified.
 
Formulation:Liquid. In PBS, pH 7.2, containing 50% glycerol and 0.09% sodium azide.
 
Handling:Avoid freeze/thaw cycles.
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:-20°C
 
Scientific Background:The nucleosome is made up of four core histone proteins (H2A, H2B, H3 and H4) and is the primary building block of chromatin. The core histones form an octamer, which is made up of one H3-H4 tetramer and two H2A-H2B dimers. The N-terminal tail of core histones undergoes different post-transcriptional modifications including acetylation, phosphorylation, methylation and ubiquitination. These modifications occur in response to cell signal stimuli and have a direct effect on gene expression.
 
Technical Info/Product Notes:Patents: USPN 6,362,317 and 6,884,873
 
905-771 WB
Western blot analysis of MW marker (1), Jurkat (2), and Jurkat + Staurosporine (3) using Histone H2AX (pSer139) pAb.
Please mouse over
905-771 WB

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
Histone
By biological activity:
Histone Polyclonal antibody
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Related Literature

Brochures
Monitor programmed cell death from membrane to nucleus
Monitor programmed cell death from membrane to nucleus
Download as PDF

Brochures
Stem Cells
Stem Cells
Download as PDF

Brochures
Epigenetics
Epigenetics
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,